These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 23504143

  • 1. Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology?
    Kurokawa Y, Shibata T, Ando N, Seki S, Mukaida H, Fukuda H.
    Ann Surg Oncol; 2013 Sep; 20(9):3009-14. PubMed ID: 23504143
    [Abstract] [Full Text] [Related]

  • 2. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
    Sato Y, Motoyama S, Nanjo H, Ito S, Yoshino K, Sasaki T, Kuribayashi K, Nagaki Y, Imai K, Saito H, Minamiya Y, Ogawa J.
    Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
    [Abstract] [Full Text] [Related]

  • 3. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
    Motoori M, Yano M, Ishihara R, Yamamoto S, Kawaguchi Y, Tanaka K, Kishi K, Miyashiro I, Fujiwara Y, Shingai T, Noura S, Ohue M, Ohigashi H, Nakamura S, Ishikawa O.
    Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
    [Abstract] [Full Text] [Related]

  • 4. Nodal skip metastasis is not a predictor of survival in thoracic esophageal squamous cell carcinoma.
    Zhu Z, Yu W, Li H, Zhao K, Zhao W, Zhang Y, Sun M, Wei Q, Chen H, Xiang J, Fu X.
    Ann Surg Oncol; 2013 Sep; 20(9):3052-8. PubMed ID: 23686016
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M, Baba Y, Yoshida N, Ishimoto T, Nagai Y, Iwatsuki M, Iwagami S, Baba H.
    Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
    Lyu X, Huang J, Mao Y, Liu Y, Feng Q, Shao K, Gao S, Jiang Y, Wang J, He J.
    J Surg Oncol; 2014 Dec; 110(7):864-8. PubMed ID: 24976079
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP.
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [Abstract] [Full Text] [Related]

  • 11. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, Meredith K.
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH, Chao YK, Chang HK, Tseng CK, Chan SC, Liu YH, Chen WH.
    Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
    [Abstract] [Full Text] [Related]

  • 14. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
    Mariette C, Taillier G, Van Seuningen I, Triboulet JP.
    Ann Thorac Surg; 2004 Oct; 78(4):1177-83. PubMed ID: 15464466
    [Abstract] [Full Text] [Related]

  • 15. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S, Tsubosa Y, Niihara M, Sato H, Takebayashi K, Kawamorita K, Mori K, Tsushima T, Yokota T, Ogawa H, Onozawa Y, Yasui H, Takeuchi H, Kitagawa Y.
    Ann Surg Oncol; 2015 Oct; 22(6):1866-73. PubMed ID: 25564176
    [Abstract] [Full Text] [Related]

  • 16. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
    Chao YK, Tseng CK, Wen YW, Liu YH, Wan YL, Chiu CT, Chang WC, Chang HK.
    Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.
    Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S.
    Jpn J Clin Oncol; 2005 Jun; 35(6):316-23. PubMed ID: 15961436
    [Abstract] [Full Text] [Related]

  • 19. Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.
    Hirst J, Smithers BM, Gotley DC, Thomas J, Barbour A.
    Ann Surg Oncol; 2011 Jun; 18(6):1766-74. PubMed ID: 21213056
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy.
    Miyata H, Yamasaki M, Makino T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y.
    J Surg Oncol; 2015 Jul; 112(1):60-5. PubMed ID: 26179950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.